Table 1.

Demographic characteristics of PsA patients at baseline, Week 12, and Week 52. Group 1 continued TNF blockers after 12 weeks. Group 2 discontinued TNF blockers after 12 weeks.

CharacteristicBaselineWeek 12Week 52
Group 1 (n = 9)Group 2 (n = 11)Group 1 (n = 9)Group 2 (n = 11)Group 1 (n = 9)Group 2 (n = 11)
Age, yrs47.8 (13.0)51.5 (11.1)
Illness duration, yrs5.7 (5.7)9.5 (7.5)
Sex, % male5463.6
Tender joint (0–68)11.2 (6.0)9.8 (4.0)3.0 (6.1)3.4 (4.4)2.0 (3.5)7.0 (10.2)
Swollen joint (0–66)4.7 (1.6)2.9 (2.5)1.2 (1.9)1.1 (1.4)02.2 (0.7)**
DAS286.14 (0.83)5.55 (0.67)2.70 (1.37)2.83 (1.28)1.24 (0.44)1.38 (0.44)**
Pain (0–100)67.8 (23.3)62.7 (16.8)14.4 (10.1)33.2 (23.5)*20.6 (20.8)49.5 (26.5)*
PGA (0–100)67.8 (20.5)58.2 (16.6)28.9 (22.6)32.3 (22.1)22.3 (21.3)42.5 (25.5)
HAQ1.16 (0.59)1.02 (0.68)0.43 (0.53)0.80 (0.74)0.50 (0.18)0.86 (0.27)
SF-36 scales
PF51.5 (23.5)57.7 (21.8)76.7 (25.0)73.3 (22.1)70.6 (30.4)54.5 (28.0)
RP19.4 (34.9)20.5 (40.0)75.0 (35.6)69.4 (42.9)59.3 (42.1)25.0 (43.3)
BP30.7 (12.5)42.8 (21.4)71.6 (20.1)54.0 (17.1)67.8 (22.4)40.2 (19.2)**
GH23.8 (8.0)40.5 (11.0)**49.6 (20.4)47.1 (13.0)44.4 (25.2)27.5 (10.6)
VT43.9 (9.3)41.8 (11.2)55.6 (21.0)45.6 (15.3)52.8 (21.4)36.4 (19.0)
SF50.1 (29.2)55.9 (31.3)77.8 (21.4)77.8 (22.3)75.0 (18.8)52.2 (27.8)
RE29.6 (42.3)24.2 (39.7)81.5 (33.8)74.1 (43.4)62.5 (37.5)21.2 (40.2)*
MH50.7 (23.1)57.5 (11.5)60.0 (20.9)68.0 (11.1)61.5 (20.7)53.2 (15.1)
PCS22.3 (7.6)28.0 (9.3)41.9 (13.3)36.6 (10.5)41.2 (16.4)26.2 (13.9)
MCS38.8 (12.6)38.8 (9.2)48.0 (13.3)49.2 (9.9)44.8 (13.4)37.2 (11.0)
  • DAS28: Disease Activity Score (28 joints); PGA: Patients assessment of global health; HAQ: Health Assessment Questionnaire; PF: physical functioning; RP: role limitation due to physical problem; BP: bodily pain; GH: general health; VT: vitality; SF: social functioning; RE: role limitation due to emotional problem; MH: mental health; PCS: physical component summary score; MCS: mental component score.

  • * If p < 0.05.

  • ** If p < 0.01.